3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
69
Multiple Myeloma
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
42
Myelodysplastic Syndromes
37
Lymphoma
37
Leukemia, Lymphocytic, Chronic, B-Cell
37
Lymphoma, Non-Hodgkin
33
Leukemia
32
Recurrence
31
Lymphoma, B-Cell
30
Melanoma
27
Lymphoma, Large B-Cell, Diffuse
22
Ovarian Neoplasms
17
Lymphoma, Mantle-Cell
17
Lymphoma, Follicular
16
Hematologic Neoplasms
16
Carcinoma, Non-Small-Cell Lung
16
Burkitt Lymphoma
16
Neoplasms
15
Lymphoma, B-Cell, Marginal Zone
13
Hodgkin Disease
13
Carcinoma, Renal Cell
12
Head and Neck Neoplasms
11
Neuroblastoma
10
Leukemia, Biphenotypic, Acute
10
Graft vs Host Disease
10
Neoplasms, Plasma Cell
9
Neoplasm Metastasis
9
Colorectal Neoplasms
9
Breast Neoplasms
9
Interventions
Nivolumab
4
Ipilimumab
4
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
CTLA-4 Antigen
3
Sunitinib
2
pembrolizumab
1
pazopanib
1
fludarabine
1
cabozantinib
1
belzutifan
1
atezolizumab
1
aldesleukin
1
Immunoglobulin G
1
Cyclophosphamide
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Clear-cell metastatic renal cell carcinoma
×
fludarabine
×
Clear all
NCT04696731
2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1
Active not recruiting
120 enrolled